Please login to the form below

Not currently logged in
Email:
Password:

PTC Therapeutics

This page shows the latest PTC Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Duchenne UK and pharma partner pilot data-sharing HTA approach

Duchenne UK and pharma partner pilot data-sharing HTA approach

Duchenne UK and pharma partner pilot data-sharing HTA approach. Pfizer, Roche and PTC Therapeutics are among those participating in Project Hercules. ... The pharma partners - Roche, Sarepta Therapeutics, Solid Biosciences, Summit and Wave Life

Latest news

  • FDA reviewer unimpressed with PTC’s Translarna FDA reviewer unimpressed with PTC’s Translarna

    FDA reviewer unimpressed with PTC’ s Translarna. Finds the muscular dystrophy treatment's evidence to be 'not persuasive'. ... PTC Therapeutics’Duchenne muscular dystrophy drug Translarna is up for an FDA advisory committee meeting on Thursday - but

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    Meanwhile, the CHMP also said that PTC Therapeutics has withdrawn its application to extend the indications for its Duchenne muscular dystrophy (DMD) drug Translarna (ataluren) to include patients with cystic fibrosis

  • Sarepta soars as FDA clears its muscular dystrophy drug Sarepta soars as FDA clears its muscular dystrophy drug

    candidates, including BioMarin's drisapersen and PTC Therapeutics' ataluren. ... Earlier this year, Sarepta Therapeutics told Muscular Dystrophy UK that they plan to apply to the EMA by the end of 2016," said the charity in a statement.

  • NICE backs PTC's muscular dystrophy drug Translarna NICE backs PTC's muscular dystrophy drug Translarna

    NICE backs PTC's muscular dystrophy drug Translarna. Drug to be available on the NHS for DMD patients aged five and over. ... Duchenne muscular dystrophy (DMD) patients and their families have welcomed a decision by NICE making PTC Therapeutics'

  • Santhera facing long delay for muscular dystrophy drug in US Santhera facing long delay for muscular dystrophy drug in US

    In recent months the FDA has rejected BioMarin's exon-skipping therapy Kyndrisa (drisapersen) - which has now been abandoned after also being turned down by the EMA - as well as PTC ... Therapeutics' Translarna (ataluren), which is already on the market

More from news
Approximately 8 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    The other asset purchase agreement was made by PTC Therapeutics, who acquired Emflaza, a steroid approved for Duchenne Muscular Dystrophy, from Marathon Pharmaceuticals for $140m upfront ($75m in cash and $65m ... 230. Marathon. PTC Therapeutics. Product

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin clearly feels that there is still a real opportunity and is prepared to take on Sarepta and PTC Therapeutics in the competition to hustle ahead new DMD drugs to regulators. ... This month also saw CAR-T “ wunder-kid” Juno Therapeutics

  • Pharma deals during January 2014 Pharma deals during January 2014

    Firstly, there was the acquisition of Merck's subsidiary, Sirna Therapeutics for $175m upfront in cash and equity. ... In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    Orchard Therapeutics appoints Mark Rothera as CEO. He joins from PTC Therapeutics. ... Prior to his new role, Rothera served as chief commercial officer at PTC Therapeutics, where he helped transition the company from a privately funded, US-based R&D

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics